Linkout box

Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !> A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.oraloncology.2020.104860

http://scihub22266oqcxt.onion/10.1016/j.oraloncology.2020.104860

32571643!7294248!32571643
    free
    free
    free

Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32571643&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215

      Oral+Oncol 2020 ; 107 (?): 104860
Nephropedia Template TP
{{tp|p=32571643|t=2020. Immunotherapy is a preferred option for oral cancer patients during COVID-19 pandemic?|pdf=|usr=}}{{32571643}}
gab.com Text
Immunotherapy is a preferred option for oral cancer patients during COVID-19 pandemic JO: Oral Oncol http://www.kidney.de/pget.php?&tw=1&pmid=32571643 #FOAvip ?
Twit Text FOAVip
Immunotherapy is a preferred option for oral cancer patients during COVID-19 pandemic ????Oral Oncol http://www.kidney.de/pget.php?&tw=1&pmid=32571643 #FOAvip
Twit Text #
Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32571643 #FOAvip
English Wikipedia
<ref>{{Cite pmid|32571643}}</ref>

Immunotherapy is a preferred option for oral cancer patients during COVID-19 pandemic? #MMPMID32571643
Chu C; Sun Y; Pan Y
Oral Oncol 2020[Aug]; 107 (?): 104860 PMID32571643show ga
?
|Adaptive Immunity/drug effects[MESH]
|Antineoplastic Agents, Immunological/*administration & dosage/adverse effects[MESH]
|B7-H1 Antigen/antagonists & inhibitors/immunology[MESH]
|Betacoronavirus/*immunology[MESH]
|COVID-19[MESH]
|Chemoradiotherapy/adverse effects/*methods[MESH]
|Coronavirus Infections/epidemiology/immunology/*prevention & control/virology[MESH]
|Humans[MESH]
|Medical Oncology/methods/standards[MESH]
|Mouth Neoplasms/immunology/*therapy[MESH]
|Pandemics/*prevention & control[MESH]
|Pneumonia, Viral/epidemiology/immunology/*prevention & control/virology[MESH]
|Practice Guidelines as Topic[MESH]
|Programmed Cell Death 1 Receptor/antagonists & inhibitors/immunology[MESH]
|Risk Assessment[MESH]
|SARS-CoV-2[MESH]Immunotherapy is a preferred option for oral cancer patients during CO(epmc).pdf

DeepDyve
Pubget Overpricing

Linkout box